AAP
PTGX icon

Arax Advisory Partners’s Protagonist Therapeutics PTGX Stock Holding History

Arax Advisory Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Buy
+95
New +$9.92K ﹤0.01% 4256
2026
Q1 		– Sell
-10
Closed -$874 – 4217
2025
Q4 		$874 Sell
10
-82
-89% -$6.71K ﹤0.01% 3517
2025
Q3 		$6.11K Buy
+92
New +$5.23K ﹤0.01% 2804
2025
Q1 		– Sell
-21
Closed -$811 – 2965
2024
Q4 		$811 Buy
+21
New +$916 ﹤0.01% 2216

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arax Advisory Partners's PTGX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 95 shares worth $11.6K. The stake represents ﹤0.01% of the portfolio and ranks #4256 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in PTGX as recently as Q4 2025.

Arax Advisory Partners first reported a position in PTGX in Q4 2024 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Arax Advisory Partners held 95 shares of Protagonist Therapeutics worth $11.6K as of Q2 2026.
  • Protagonist Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4256 holding.
  • Arax Advisory Partners first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.